Navigation Links
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Date:3/7/2009

upport for continuing to develop NVC-422 for fungal infections."

NVC-422 is the most advanced of a series of compounds from a new class of drugs that mimics the body's natural defense against infection. NVC-422 may deliver the same or better efficacy as currently used antibiotics without contributing to the growing rise of bacterial resistance. The Company plans to file an exploratory Investigational New Drug application with the U.S. Food and Drug Administration in the second quarter of 2009 and initiate a Phase II clinical trial of NVC-422 during the second half of 2009 for impetigo, one of the most common skin infections among children, which produces blisters or sores on the face, neck, hands and diaper area.

"The ability to treat infection with a non-antibiotic is more important than ever because of the rise of drug resistant bacteria," said Dr. Ron Najafi, chairman and chief executive officer of NovaBay. "In developing anti-infective compounds, experience shows that preclinical results are more predictive of clinical efficacy than in other therapeutic categories, and I am encouraged that our preclinical work to date strongly suggests that NVC-422 may be a potent and well-tolerated treatment for numerous serious skin infections such as acne, nail fungus and topical viral infections, where antibiotics are not effective. Advancing NVC-422 into Phase II clinical trials reinforces the strength of our extensive preclinical work and, significantly, redefines NovaBay as a mid-stage biotech company."

NovaBay's experienced researchers have created a pipeline and research and development engine of first-in-class, broad-spectrum anti-bacterial and anti-fungal agents with low to no microbial resistance. In-vitro studies to date have shown that NVC-422 has a potentially expansive therapeutic utility against bacteria of all types, including multidrug resistant species; shedding viruses including adenoviruses; and
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
3. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... June 29, 2015 Research ... the "Pharmaceutical Grade Sodium Chloride Market by Applications, ... report to their offering. The pharmaceutical ... CAGR of 6.9% between 2014 and 2019 in terms ... 690 KT by 2019. The report on ...
(Date:7/6/2015)... -- Celtaxsys, Inc., a clinical stage pharmaceutical development company ... orphan inflammatory disease indications, announced today that it has ... (FDA) to begin a Phase 2 clinical trial of ... patients in the US. The regulatory submissions to the ... be filed soon after. This groundbreaking clinical study, testing ...
(Date:7/6/2015)... -- Akcea Therapeutics, a wholly-owned subsidiary of Isis ... that the U.S. Food and Drug Administration has ... ) for the treatment of patients with Familial ... disease characterized by extremely high triglyceride levels and ... published in the NEJM in December 2014, patients ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 2Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 3Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 4Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 5Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome 6
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report titled ... by the time they turn age 35 a quarter of all women in the U.S. will ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, who ...
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: ... there is a large gap between the unmet health priorities in the region ... outcomes and reduce unnecessary or ineffective treatments or procedures. , This milestone conference, ...
(Date:7/6/2015)... ... July 06, 2015 , ... Olive Fertility Centre is proud ... Post Graduate Teaching Award on behalf of the department of Family Practice. , “This ... field to be practicing in. The technology is changing so rapidly and we are ...
(Date:7/6/2015)... ... July 06, 2015 , ... Longevity, the highest regarded provider ... Walk-In Urgent Care to offer on-site health screenings. These ultrasound screenings detect early ... affordable and accurate and run about an hour long with same day results. ...
(Date:7/6/2015)... ... July 06, 2015 , ... Health care systems and genomics projects ... medical field to access and use this “Big Data” to improve health and cut ... Executive Officer of the Mount Sinai Health System in New York City. Physicians will ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 2Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 3Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 4Health News:Mount Sinai CEO Kenneth L. Davis, MD: Our Ability to Access Information in Real Time to Prevent Disease is Drawing Closer 5
... Life Sciences has submitted an application with the Drug ... phase-1 clinical trials of its new drug Suvn-502 for ... ,'Treatment for Alzheimer's disease and Schizophrenia is ... to discover drugs that address significant unmet medical needs,' ...
... Nepalese doctors has developed a drug that is more ... reported Friday . ,The drug also costs ... Organization (WHO), reported The Himalayan Times daily.Doctors at the ... typhoid patients. ,,The team compared the effectiveness ...
... 1,763 food shipments from India, 1,480 from Mexico and 1,368 ... year . ,Some of India's spices, seeds and ... found too filthy to eat. Chinese products like seafood, bean ... has reported. ,,But the FDA did not reveal the ...
... for the high-tech dental lasers used mainly to prepare cavities ... conducted by researchers in Austria, these advanced dental lasers can ... study credits the progress of miniaturized, flexible fiber tips for ... treatment. ,Dr. Ulrich Schoop and a team of ...
... on the Yamuna River that flows past India's capital, it's easy ... surface by rotting sewage -- and that's after at least ... ,Now, with New Delhi to host the Commonwealth Games in ... built on the stinking river's banks, India must do in three ...
... the end of the last century death rates from breast ... Long waiting lists, resulting in delayed diagnosis and treatment, were ... is failing breast cancer patients and needs to be reviewed ... brought in the 2 week wait rule which stipulated that ...
Cached Medicine News:Health News:US Rejects More Food from India Than from Any Other Country 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 2Health News:Millions Spent, but the Indian Capital's River Still Stinks 3Health News:Two Week Wait Rule Not Working With Breast Cancer Patients 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: